The GBG 26 - TBP study of the German Breast Group addressed the question of whether the treatment of women with HER2-positive metastatic breast cancer with trastuzumab is effective beyond progression (Trastuzumab Beyond Progression TBP).
The details can be read here.
No comments:
Post a Comment